To determine the extent to which clinically significant prostate cancer (csPCa) can be detected in a routine National Health Service setting in men with no previous biopsy, when multiparametric magnetic resonance imaging (mpMRI) is introduced into the diagnostic pathway.
Introduction
Multiparametric MRI (mpMRI) of the prostate has proven promising with the potential to personalise detection, localisation, and treatment of prostate cancer (PCa). mpMRItargeted biopsies have a greater efficacy than standard TRUSguided biopsy and have been used in cohorts of patients under active surveillance and those with previous negative biopsies yet a rising PSA level [1, 2] . Studies suggest mpMRI has a high negative predictive value (NPV) for PCa and may be more cost-effective and less intrusive to patients when used before the first biopsy [3] [4] [5] ; therefore, an increasing number of centres are incorporating mpMRIs into the initial diagnostic pathway for men with suspected PCa. An additional advantage is the avoidance of post-biopsy artefact caused by haemorrhages within the prostate, as such changes make it harder to accurately characterise lesions in subsequent mpMRIs and can reduce the sensitivity of the scan [1] .
Another area of clinical interest is reducing the potential for over-diagnosis of 'clinically insignificant' disease in men suspected of having PCa. In a percentage of cases, the cancer is indolent enough so as not to pose health issues within an individual's lifetime [6, 7] . Prostate biopsy can itself lead to complications such as sepsis and, in certain circumstances, subsequent overtreatment that carries with it the risk of incontinence, erectile dysfunction, and other post-biopsy complications [7] . In addition, the Prostate Testing for Cancer and Treatment (ProtecT) study [8] , which compared treating PCa with active monitoring, radiotherapy and radical prostatectomy, found no significant differences in the PCaspecific mortality at 10 years of follow-up.
Most existing mpMRI data are derived from research-driven protocols. The primary aim of our present case series was to determine the extent to which clinically significant PCa (csPCa), defined as Gleason score ≥3+4, could be detected in a routine clinical setting when pre-biopsy mpMRI was incorporated in the diagnostic pathway. This was determined using mpMRI in men with no previous biopsy and abnormal PSA level and/or DRE, using biopsy findings as the reference standard. Other aims were to establish the diagnostic utility of mpMRI in PCa. We hypothesised that mpMRI would detect csPCa well and could be used in the initial investigations to inform the decision to undergo a prostate biopsy [1, 2, 9 ].
Patients and Methods
Where possible, this case series adhered to Standards of Reporting for MRI-targeted Biopsy Studies (START) [10] guidelines. We used a prospectively designed database to improve the methodology and used a combination of electronic patient records to source data retrospectively.
Patients
Inclusion criteria were men with no prior biopsy in whom a mpMRI was performed on account of a clinical suspicion of PCa. Clinical suspicion was indicated by an elevated serum PSA level (greater than age-related values) or an abnormal DRE. The population consisted of patients who underwent prostate mpMRI examinations between 28 July 2013 and 19
April 2016. Exclusion criteria comprised previous mpMRIs, previous biopsies, and incomplete mpMRI scans (Fig. 1) . All data were collected retrospectively from electronic patient records. Data collected included age at mpMRI, PSA level, and DRE findings.
mpMRI Conduct
A Siemens Avanto mpMRI scanner, with a field strength of 1.5 T, was used to image the prostate and surrounding areas. A body array coil was used. Sequences obtained included T2-weighted imaging (axial and coronal planes, 3-mm thickness), axial diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) (T1 VIBE). DCE acquisitions were qualitatively assessed with 12 acquisitions carried out over 3 min and 26 s, i.e. 17 s/acquisition. DWI b-values comprised of 50, 800 and 1 400, and apparent diffusion coefficient mapping was assessed qualitatively. mpMRIs were reported according to the Prostate Imaging Reporting and Data System (PI-RADS) [11] . This system facilitates standardised reporting and reduces subjectivity in assessment [5, 11] . Individual lesions were given a PI-RADS score, then an overall PI-RADS score for the scan ranging from 1 to 5, as determined by the highest scoring lesion (Table 1) [11] .
Abnormalities of the prostate were reported in prose and significant lesions were identified by the radiologist. Lesion location in the prostate was described by dividing the gland into 12 segments; left and right, basal, mid and apical, anterior or posterior. Lesions were drawn on a prostate MRI template map (Appendix S1), which was used to facilitate targeting during biopsy. PI-RADS scores were retrospectively assigned when the score was absent from the mpMRI report (in the early part of the present series, PI-RADS scoring was not routine). The radiologist had access to the original reports but had no knowledge of the biopsy results or final clinical outcomes. Most of the retrospectively assigned PI-RADS were scored a 1 or 2 to indicate csPCa was highly unlikely or unlikely to be present, respectively. One radiologist retrospectively assigned PI-RADS scores to both his own original reports and the original reports of his colleagues, where required. Five radiologists, with up to 10 years' experience reporting prostate MRIs and 5 years of reporting mpMRIs reported on the scans.
Prostate Biopsy
After the mpMRI, patients underwent either TRUS-guided or transperineal biopsy. If the mpMRI indicated a posterior lesion, a targeted TRUS-guided biopsy was taken. If the mpMRI indicated an anterior lesion, a transperineal biopsy was taken. Men with negative mpMRIs but a significant clinical risk were offered a routine TRUS-guided biopsy. Men with negative mpMRIs and a low clinical risk were less likely to undergo biopsy at our centre. TRUS-guided biopsies were carried out with antibiotic prophylaxis as per local guidelines under local anaesthetic using the standard 12-core biopsy or using a range of standard and targeted cores. Transperineal biopsies were carried out under general anaesthetic with antibiotic prophylaxis and the a-blocker tamsulosin, as per local guidelines.
Both TRUS-guided and transperineal biopsies were taken via cognitive fusion aided with lesions recorded on the prostate MRI template map from the radiology report. mpMRI results were available to the physician conducting the biopsy and our study assumes the location of the lesion was looked at if present according to best clinical practice.
Definition of csPCa
csPCa was defined as Gleason score ≥3+4 at our centre. csPCa has also commonly been defined by a maximum cancer core length involvement of ≥6 mm in other studies [12] ; however, this variable is not reported at our centre.
Data Analysis
Our primary objective was to assess the ability of mpMRI to detect or exclude csPCa defined as Gleason score ≥3+4 in a routine clinical setting. A mpMRI PI-RADS score of ≥3-5 was considered positive. Sensitivity, specificity, positive predictive value (PPV) and NPV were calculated with 95% CIs. Descriptive statistics were used to summarise patient characteristics such as age, PSA, DRE, prostate volume. PSA densities (PSADs) were calculated (PSA level/prostate volume). PSA levels were categorised in to the following groups, <5, 5-9.99, and ≥10 ng/mL. PSADs were categorised in to the following groups: <0.12, 0.12-0.149 and ≥0.15 ng/ mL/mL.
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSSâ), version 22.0 (SPSS Inc., IBM Corp., Armonk, NY, USA). Diagnostic accuracy calculations were performed using StatsDirect software, version 11 (StatsDirect Ltd, Cheshire, UK). Chi-squared tests for independence were used to assess for an association between the detection of PCa and other variables such as prostate volume, primary lesion size on MRI, and PSAD. P values <0.05 were considered significant.
Results

Descriptive Statistics
In all, 1023 patients meeting the inclusion criteria underwent mpMRI prostate examinations between 28 July 2013 and 19 April 2016; 792 men subsequently underwent biopsy, of which 106 were transperineal. The median number of cores taken in transperineal and TRUS-guided biopsy were 10 and 6, respectively. The median (interquartile range [IQR] ) time between mpMRI and either TRUS-guided or transperineal biopsy was 28 (20) days. Table 2 provides the baseline clinical characteristics of patients who underwent mpMRI only and mpMRI followed by biopsy.
In men with PI-RADS 4-5, the reasons why biopsies were not performed include obvious csPCa, older patient cohort or patient declined a biopsy. As this was an observational study, the decision to biopsy was at the discretion of the clinician and patient. Tables 3 and 4 show the descriptive statistics of benign, insignificant and csPCa in terms of age and DRE.
Detection Rates of csPCa (Gleason Score ≥3+4) csPCa and PCa of any grade were detected in 37% (290/792) and 53% (421/792) of men, respectively. mpMRI PI-RADS Figure 2 shows the association between different PI-RADS scores and biopsy findings based on the significance of PCa detected. csPCa rises from 14.6% of PI-RADS 1% to 86.1% of PI-RADS 5.
Of the men with normal mpMRIs (PI-RADS 1-2) and csPCa, PSA levels of ≥5 ng/mL and PSADs of ≥0.12 ng/mL/mL were seen in 80% and 80% of men, respectively. In all, 20% of men with normal mpMRIs and csPCa had a PSA level of ≥10 ng/mL and 63% had a PSAD of ≥0.15 ng/mL/mL. Conversely, 69% of men with normal mpMRIs and insignificant PCa or benign biopsies had a PSA level of ≥5 ng/mL and 45% had a PSAD of ≥0.12 ng/mL/mL; 13% had a PSA level of ≥10 ng/mL and 29% had a PSAD of ≥0.15 ng/mL/mL (Tables 5 and 6 ).
For men with PI-RADS 3 and csPCa, 24% had a PSA level of ≥10 ng/mL, and 61% had a PSAD of ≥0.15 ng/mL/mL.
There was an association between PSAD and the presence of PCa on biopsy (chi-squared P < 0.05). PSADs of ≥0.15 ng/mL/mL were associated with csPCa and PSADs of <0.12 ng/mL/mL were more commonly associated with benign and insignificant cancer.
A chi-squared test showed an association between prostate volumes on mpMRI and the presence of PCa at biopsy (chisquared P < 0.05). Benign biopsies were associated with larger prostate volumes than expected and csPCa was associated with smaller prostate volumes than expected. There was no association between the primary lesion size on mpMRI and the presence of PCa on biopsy (chi-squared P = 0.26).
Comparison of Patients with Normal and Abnormal mpMRIs
Biopsies revealed 100% ( 
*T1, T2, T3, T4 refer to the size of the main tumour; the higher the number after the T, the larger the tumour. In Fig. 4 , a breakdown of cases with Gleason score 7 PCa but a normal mpMRI (PI-RADS 1-2) shows that 84% were of a 3+4 pattern and the remaining 16% were of a 4+3 pattern.
Diagnostic Test Analysis
In excluding csPCa (Gleason ≥3+4), mpMRI had a specificity of 59.0% (95% CI 54.5-63.3%) and a NPV of 85.1% (95% CI 81.5-88.0%; Table 7 ). In excluding csPCa, mpMRI had a sensitivity of 82.1% (95% CI 77.2-86.3%) and a PPV of 53.6% (50.7-56.5%). The assumption that a benign or insignificant biopsy indicates the absence of disease was made.
Discussion
The present case series aimed to determine the extent to which csPCa, defined as a Gleason score of ≥3+4, can be detected in a routine clinical setting in men with no previous biopsy when mpMRI is introduced into the diagnostic pathway. This was assessed by comparing mpMRI PI-RADS scores to biopsy findings as the reference standard. Our present results are similar to data from published research trials and support the proposed patient benefits of the use of mpMRI in initial investigations as more csPCa was detected in patients assigned PI-RADS 4 and 5. 
% of paƟents
Normal mpMRI (PI-RADS 1-2) Abnormal mpMRI (PI-RADS 3-5) The overall detection rate of csPCa in 37% of cases is consistent with the published literature in routine clinical settings [13] . In detecting and excluding csPCa, expected trends were seen. The higher the PI-RADS score, the more clinically significant the PCa detected. However, a normal scan did not exclude disease, as 14.6% of PI-RADS 1 cases and 15.7% of PI-RADS 2 cases had csPCa at biopsy.
In men with normal mpMRIs, 17.0% had palpable disease and 75.5% of these had Gleason score 3+4 PCa at biopsy. Seven patients (13.2%) had high-risk PCa according to the D'Amico criteria [14] with the remaining patients having intermediate-risk disease.
Notably, 63% of men with normal mpMRIs and csPCa had a PSAD of ≥0.15 ng/mL/mL, whilst only 29% of men with insignificant or benign biopsies had a PSAD of ≥0.15 ng/mL/ mL. There was also a significant association between PSADs and the presence of PCa at biopsy (P < 0.05). This suggests that there may be merit in exploring the relationship between PSAD and mpMRI results in future studies to further refine test reliability. Evaluation of PSA level alone produced a smaller difference suggesting that PSADs should be considered to improve prediction of csPCa, triage men, and reduce unnecessary biopsies [1, 15, 16] .
Over 90% of men diagnosed with Gleason score 8, 9 and 10 had an abnormal mpMRI, demonstrating that the scan performs well in detecting high-grade csPCa. mpMRI performed less well in lower grade csPCa, as 14% of Gleason score 7 cancers had normal mpMRIs. However, further analysis of the Gleason score 7 cases assigned a normal mpMRI revealed that 84% were associated with a Gleason score of 3+4 (rather than 4+3), which according to University College London (UCL) definition 1 is considered to be 'clinically insignificant cancer' [17] . The definition of csPCa varies across centres and when defined by Gleason score, ranges from any pattern ≥4 (UCL definition 2) to a primary pattern ≥4 (UCL definition 1) [9, 17, 18] . Re-assessment of our present data using UCL definition 1 results in the number of csPCa assigned a normal mpMRI dropping to 2.9% in the present series. Whilst the NPV using our present definition is consistent with the results of other studies [13, 19] , research suggest this definition is too conservative leading to over diagnosis and overtreatment of low-grade PCa that is unlikely to cause clinical concerns if left untreated in a patient. Insignificant PCa is also less likely to be detected by mpMRI [20] , possibly due to spatial resolution limitations [21] [22] [23] . However, the overall relationship in terms of benefit vs harm is likely to favour scanning, as the problems associated with overtreatment represent the greater challenge [9] .
Benign biopsies were associated with larger prostate volumes than expected and csPCa was associated with smaller prostate volumes than expected, which fits previous evidence in cases of BPH [24] .
Diagnostic Test Analysis
Diagnostic test analysis revealed a high sensitivity (82%) and NPV (85%), and lower specificity (59%) and PPV (54%). Given that an initial screening test requires a high sensitivity and NPV, mpMRI appears to be a useful modality for improving the detection of csPCa.
Our present findings are consistent with a study carried out in a routine clinical setting [13] , in which 129 biopsy-na€ ıve men with clinical suspicion of PCa underwent mpMRI followed by a transperineal biopsy. Sensitivity, NPV, 
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© 2018 The Authors BJU International © 2018 BJU International specificity and PPV were 93%, 92%, 21% and 24%, respectively. Participant selection bias arose as the prevalence of PCa was abnormally high in the study. This was because the majority of patients with a normal mpMRI were excluded, as they opted for TRUS-guided biopsy as opposed to a transperineal biopsy.
In clinical trials, where csPCa was also defined as Gleason score ≥3+4, our present results are concordant. The PROstate MRI Imaging Study (PROMIS) [12] reported a high sensitivity (88%) and PPV (65%) and a lower specificity (45%) and NPV (76%). Some trials had a slightly higher sensitivity [12, 13, 25] , and a higher NPV [13, 25] than that seen in our present series, most likely due to the use of transperineal biopsy as the reference standard, which reduces the false-negative rate compared to TRUS-guided biopsy [26] . However, TRUSguided biopsies are more common in routine practice and the use of general anaesthesia during transperineal biopsies can introduce additional complications [27, 28] .
Our present data have been gathered from a routine clinical setting, rendering our findings applicable to day-to-day practice, which is a major strength of the present case series.
To the best of our knowledge, there are no other similar studies of this scale, as the majority report smaller sample sizes, which increase the potential for error.
Limitations
First, it was not possible to satisfy every recommendation of the START guidelines. Due to the retrospective nature of our data collection, core length was not recorded, as it is not reported at our centre. Second, 634 PI-RADS scores had to be retrospectively assigned. This is mainly because, in the early part of the series, we had not formally adopted the PI-RADS scoring system, in common with many other UK centres. Additionally, many mpMRIs were reported as 'normal' or 'BPH' rather than a specified PIRADS score of 1 or 2 in the early adoption phase. Third, PSA levels and PSADs were available in 99% and 80% of men in the present study, respectively. Fourth, men with low mpMRI PI-RADS were less likely to undergo biopsy; and whilst this selection bias may overestimate the detection rate of csPCa, this reflects the shared decisions patients and clinicians make in day-to-day practice outside of research centres. Fifth, one in eight men had a transperineal biopsy performed rather a TRUSguided biopsy. This technique is known to have a higher detection rate of cancer and there is potential for it to increase the likelihood of abnormal scans being associated with a PCa diagnosis. Sixth, biopsies were targeted with mpMRI using a cognitive approach, which while increasing detection rates of PCa compared to TRUS-guided biopsy alone [29] , is less accurate than MRI/ultrasonography-fusion targeted prostate biopsies that fuse mpMRI scans with real-time ultrasonography images of the prostate for improved imaging [30] . Finally, whilst reporting acumen was consistent during the present study, inter-reporter variability is likely to exist and more uniformity in reporting is needed.
Clinical Implications
Despite these limitations, the present study provides valuable insight into the use of mpMRI in the initial investigation of men with a clinical suspicion of PCa. The low specificity and PPV of the test suggest mpMRI cannot be used to confirm disease instead of biopsies. However, mpMRI provides a riskfree way of evaluating the prostate gland and the NPV suggests mpMRI could inform decision making over whether to avoid biopsy, especially in instances where mpMRI results are normal. If the definition of csPCa is amended in the future, the NPV will become arguably higher and strengthen the basis of mpMRI as a triage test.
The results of the PROMIS trial [12] show mpMRI's utility as a pre-diagnostic triage test. Whilst the established PI-RADS scoring system standardises mpMRI and makes its use generalisable, studies suggest that disparities in radiologist reporting, access to scanners, and the way mpMRI-targeted biopsies are conducted, occurs across centres. Similar standardised protocols need to be developed for all aspects involved in initial investigations using mpMRI for quality assurance.
Conclusion
mpMRI has a significant role to play in the contemporary management of men with suspected PCa. It has the potential to delineate the most appropriate course of action during initial investigations, improving the detection rate of csPCa, and possibly reduce the risk of over diagnosis and subsequent overtreatment.
Further research is needed in the group of men with normal mpMRIs to establish if there is a statistically significant difference in the PSADs of men with csPCa and those without csPCa; this may help to inform the discussion with such men and to develop an algorithm to aid triaging of patients.
